Last reviewed · How we verify
Preservative Free drop treatment
A preservative-free ophthalmic drop formulation that delivers therapeutic agents directly to the eye without chemical preservatives.
A preservative-free ophthalmic drop formulation that delivers therapeutic agents directly to the eye without chemical preservatives. Used for Dry eye disease, Glaucoma (preservative-free formulation), Allergic conjunctivitis.
At a glance
| Generic name | Preservative Free drop treatment |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Preservative-free drops eliminate the use of antimicrobial agents (such as benzalkonium chloride) that can cause ocular surface irritation and toxicity with chronic use. This formulation is typically delivered via single-dose units or special packaging systems that maintain sterility without preservatives, reducing local toxicity while maintaining therapeutic efficacy for the active ingredient.
Approved indications
- Dry eye disease
- Glaucoma (preservative-free formulation)
- Allergic conjunctivitis
- Post-operative ocular care
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Transient blurred vision
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia (PHASE4)
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
- Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis (PHASE3)
- Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: